Cart
sales@molnova.com
Oxepinac
CAS No. 55689-65-1
Oxepinac( —— )
Catalog No. M35997 CAS No. 55689-65-1
oxepinac is an effective and well-tolerated compound for the treatment of painful osteoarthritis. oxepinac has no teratogenic effect on mouse and rabbit fetuses in animal experiments.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 365 | Get Quote |
|
| 5MG | 561 | Get Quote |
|
| 10MG | 801 | Get Quote |
|
| 25MG | 1178 | Get Quote |
|
| 50MG | 1592 | Get Quote |
|
| 100MG | 2097 | Get Quote |
|
| 500MG | 4203 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameOxepinac
-
NoteResearch use only, not for human use.
-
Brief Descriptionoxepinac is an effective and well-tolerated compound for the treatment of painful osteoarthritis. oxepinac has no teratogenic effect on mouse and rabbit fetuses in animal experiments.
-
Descriptionoxepinac is an effective and well-tolerated compound for the treatment of painful osteoarthritis. oxepinac has no teratogenic effect on mouse and rabbit fetuses in animal experiments.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number55689-65-1
-
Formula Weight268.26
-
Molecular FormulaC16H12O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C=2C(=CC(CC(O)=O)=CC2)OCC=3C1=CC=CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PKG Substrate
PKG Substrate is a selective substrate for cGMP-dependent protein kinase (PKG).PKG Substrate is a selective substrate for protein kinase G (PKG) with a strong preference for PKG Iα (Km = 59 μM) over PKG II (Km = 305 μM).
-
Enpatoran hydrochlor...
Enpatoran (M5049) hydrochloride is a potent, orally active dual inhibitor of TLR7/8 with IC50 values of 11.1 nM and 24.1 nM in HEK293 cells, respectively.
-
CRSP-1
Endogenous central calcitonin (CT) receptor agonist that stimulates cAMP formation at a potency 350-fold greater than CT (ED50 values are 0.2 and 71 nM respectively). Displays no activity at calcitonin-gene related peptide (CGRP) and adrenomedullin receptors. Inhibits formation of multinuclear osteoclasts with similar efficacy to CT in vitro. Suppresses food intake and increases body temperature in free-feeding rats, and significantly decreases plasma calcium levels in vivo.
